Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric
antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 …
antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 …
Management of relapsed–refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice
Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …